



12 January 2006

Sinclair Pharma plc

Change of Broker

Sinclair Pharma plc (LSE: SPH) ("Sinclair" or the "Company"), the specialty pharmaceuticals company, today announces that, with immediate effect, Nomura International plc is no longer acting as joint broker to the Company.

Piper Jaffray Ltd. will continue in its existing role as nominated adviser and joint broker to the Company and Bridgewell Securities Limited will continue in its role as joint broker.

- Ends -

Enquiries:

Sinclair Pharma plc
Michael Flynn, Chief Executive Officer
Jerry Randall, Chief Financial Officer

Tel: 01483 426644

Financial Dynamics
Ben Attwell

Tel: 020 7831 3113

Further information on Sinclair can be found on the company's website:
www.sinclairpharma.com